❓WHAT HAPPENED: Over 580,000 bottles of prazosin hydrochloride, a blood pressure medication, were recalled due to potential contamination with a cancer-causing chemical.
👤WHO WAS INVOLVED: Teva Pharmaceuticals USA, Amerisource Health Services, and the Food and Drug Administration (FDA).
📍WHEN & WHERE: Nationwide recall issued earlier this month by New Jersey-based Teva Pharmaceuticals and Amerisource Health Services.
🎯IMPACT: The recall affects patients using prazosin for blood pressure and PTSD-related sleep disturbances, raising concerns over drug safety.
The Food and Drug Administration (FDA) has announced the recall of over 580,000 bottles of prazosin hydrochloride, a blood pressure medication, due to concerns over the presence of a potentially cancer-causing chemical. The medication, which is also prescribed for sleep disturbances related to post-traumatic stress disorder (PTSD), was voluntarily recalled by New Jersey-based Teva Pharmaceuticals USA and drug distributor Amerisource Health Services.
The affected capsules, available in 1 mg, 2 mg, and 5 mg doses, were classified by the FDA as a Class II risk. According to the agency, some lots of the medication may contain nitrosamine impurities, which can form during manufacturing or storage and are considered potentially carcinogenic.
The FDA’s recall orders, posted on its website, highlight the potential risks associated with the medication. Teva Pharmaceuticals has not yet responded to requests for comment regarding the recall.
Patients who rely on prazosin hydrochloride for managing blood pressure or PTSD-related conditions are now left questioning the safety of their medication. The recall underscores broader concerns about the pharmaceutical supply chain and the need for stringent oversight in drug manufacturing and storage processes.
Join Pulse+ to comment below, and receive exclusive e-mail analyses.
